Synergistic effects were observed in the co-transfection with mRNAs encoding anti-CTLA-4 and anti-PD-1 mAbs, which were associated with higher overall response rates and greater changes in tumor burden compared to single agent treatment, conferring it as the first FDA-approved treatment for advanced-staged melanoma [267,268]. The gene discussed is CTLA4; the disease is melanoma.